These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 19485752)

  • 21. Assessment of postlicensure safety of rotavirus vaccines, with emphasis on intussusception.
    Bines JE; Patel M; Parashar U
    J Infect Dis; 2009 Nov; 200 Suppl 1():S282-90. PubMed ID: 19817611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New challenges in assuring vaccine quality.
    Dellepiane N; Griffiths E; Milstien JB
    Bull World Health Organ; 2000; 78(2):155-62. PubMed ID: 10743279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guillain-Barré syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005).
    Souayah N; Nasar A; Suri MF; Qureshi AI
    J Clin Neuromuscul Dis; 2009 Sep; 11(1):1-6. PubMed ID: 19730016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Guidelines for reporting adverse events associated with vaccine products. Division of Immunization, Bureau of Infectious Diseases, Laboratory Center for Disease Control.
    Can Commun Dis Rep; 2000 Feb; 26 Suppl 1():I-IV, 1-18. PubMed ID: 11055081
    [No Abstract]   [Full Text] [Related]  

  • 25. [Pharmacovigilance of vaccines].
    Autret-Leca E; Bensouda-Grimaldi L; Jonville-Béra AP; Beau-Salinas F
    Arch Pediatr; 2006 Feb; 13(2):175-80. PubMed ID: 16343870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Surveillance of secondary effects of vaccination].
    Duclos P
    Sante; 1994; 4(3):215-20. PubMed ID: 7921691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New approaches in vaccine development.
    Leclerc C
    Comp Immunol Microbiol Infect Dis; 2003 Oct; 26(5-6):329-41. PubMed ID: 12818620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of vaccine safety after the events of 11 September 2001: role of cohort and case-control studies.
    Chen RT
    Vaccine; 2004 May; 22(15-16):2047-53. PubMed ID: 15121321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring.
    Vellozzi C; Burwen DR; Dobardzic A; Ball R; Walton K; Haber P
    Vaccine; 2009 Mar; 27(15):2114-20. PubMed ID: 19356614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ensuring the optimal safety of licensed vaccines: a perspective of the vaccine research, development, and manufacturing companies.
    Kanesa-thasan N; Shaw A; Stoddard JJ; Vernon TM
    Pediatrics; 2011 May; 127 Suppl 1():S16-22. PubMed ID: 21502248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccine side effects: fact and fiction.
    Day MJ
    Vet Microbiol; 2006 Oct; 117(1):51-8. PubMed ID: 16701964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007.
    Niu MT; Ball R; Woo EJ; Burwen DR; Knippen M; Braun MM;
    Vaccine; 2009 Jan; 27(2):290-7. PubMed ID: 18992783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tracking vaccine-safety inquiries to detect signals and monitor public concerns.
    Miller E; Batten B; Hampton L; Campbell SR; Gao J; Iskander J
    Pediatrics; 2011 May; 127 Suppl 1():S87-91. PubMed ID: 21502241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Intensive Vaccines Monitoring Programme (IVMP): an electronic system to monitor vaccine safety in New Zealand.
    Tatley MV; Kunac DL; McNicholas A; Zhou L; Ballantyne S; Ashton J; Stehr-Green P; Galloway Y; Reid S
    Vaccine; 2008 May; 26(22):2746-52. PubMed ID: 18430496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Adverse events after vaccination].
    Nøkleby H; Bergsaker MA
    Tidsskr Nor Laegeforen; 2006 Oct; 126(19):2541-4. PubMed ID: 17028637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccine adverse event monitoring systems across the European Union countries: time for unifying efforts.
    Zanoni G; Berra P; Lucchi I; Ferro A; O'Flanagan D; Levy-Bruhl D; Salmaso S; Tridente G
    Vaccine; 2009 May; 27(25-26):3376-84. PubMed ID: 19200851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Postmarketing surveillance of secondary effects of vaccines].
    Duclos P
    Rev Epidemiol Sante Publique; 1994; 42(5):425-33. PubMed ID: 7973002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monitoring the safety of a smallpox vaccination program in the United States: report of the joint Smallpox Vaccine Safety Working Group of the advisory committee on immunization practices and the Armed Forces Epidemiological Board.
    Neff J; Modlin J; Birkhead GS; Poland G; Robertson RM; Sepkowitz K; Yancy C; Gardner P; Gray GC; Maurer T; Siegel J; Guerra FA; Berger T; Flanders WD; Shope R; ;
    Clin Infect Dis; 2008 Mar; 46 Suppl 3():S258-70. PubMed ID: 18284367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccine adverse events in the new millennium: is the sky really falling?
    Hinman AR
    Bull World Health Organ; 2000; 78(2):221-2. PubMed ID: 10743291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measuring vaccine confidence: analysis of data obtained by a media surveillance system used to analyse public concerns about vaccines.
    Larson HJ; Smith DM; Paterson P; Cumming M; Eckersberger E; Freifeld CC; Ghinai I; Jarrett C; Paushter L; Brownstein JS; Madoff LC
    Lancet Infect Dis; 2013 Jul; 13(7):606-13. PubMed ID: 23676442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.